Bio-Techne (NASDAQ:TECH) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Bio-Techne (NASDAQ:TECH) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.02), FiscalAI reports. The company had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.08 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same quarter last year, the company posted $0.56 earnings per share.

Here are the key takeaways from Bio-Techne’s conference call:

• Company reported a 2% organic revenue decline in Q3 but improved profitability with adjusted operating margin of 34.2%; management says the quarter faced ~400 bps of timing headwinds and that underlying organic growth was +2% excluding those items.
• Spatial biology (COMET) delivered >65% growth with a record backlog and the first COMET installed in China, positioning the platform for continued expansion.
• Excluding two Fast Track cell therapy customers, the GMP protein portfolio grew nearly 50% year-over-year, and Bio?Techne plans to acquire the remainder of Wilson Wolf (G?Rex bioreactors) by end of 2027 to bolster cell therapy manufacturing exposure.
• Emerging biotech spending remains the largest downside risk — revenues were weak (high-single-digit decline) despite recent strong funding trends, which management says typically take 2–3 quarters to translate into customer spending and expects a meaningful recovery in fiscal 2027.

Bio-Techne Stock Down 17.5%

Shares of TECH stock traded down $9.89 on Wednesday, reaching $46.79. 8,089,959 shares of the company were exchanged, compared to its average volume of 2,383,219. The company has a market cap of $7.32 billion, a price-to-earnings ratio of 91.91, a PEG ratio of 3.60 and a beta of 1.41. The company has a 50-day moving average of $54.70 and a 200-day moving average of $59.71. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.54 and a quick ratio of 3.08. Bio-Techne has a one year low of $45.12 and a one year high of $72.16.

Wall Street Analyst Weigh In

TECH has been the subject of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Bio-Techne in a report on Tuesday, March 17th. Wells Fargo & Company increased their price objective on Bio-Techne from $70.00 to $76.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Benchmark reiterated a “buy” rating on shares of Bio-Techne in a report on Tuesday, February 3rd. Finally, Stifel Nicolaus set a $65.00 price target on Bio-Techne and gave the stock a “hold” rating in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $72.77.

Bio-Techne News Summary

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Operating profitability improved (GAAP EPS rose year over year and management highlighted operating?margin expansion), which supports near?term earnings quality. Read More.
• Positive Sentiment: Several growth vectors performed well — large pharma (double?digit growth), Spatial Biology (mid?teens), Proteomic Analysis instruments (mid?single digits) and GMP proteins (nearly 50% ex?fast?track) — which can support longer?term revenue recovery. Read More.
• Positive Sentiment: The board declared a quarterly cash dividend of $0.08 per share, which is supportive for income?oriented holders. Read More.
• Neutral Sentiment: Management explained the revenue miss as partly due to timing of large Commercial Supply shipments and a prior?year tailwind from GMP fast?track orders — an operational timing issue that may reverse in future quarters. Read More.
• Negative Sentiment: Revenue and adjusted EPS missed consensus: revenue $311.4M vs. ~$316M expected and adjusted EPS $0.53 vs. $0.55 expected; reported revenue declined ~2% year?over?year — the primary catalyst for the selloff. Read More.
• Negative Sentiment: Demand headwinds from cuts to U.S. academic funding and weaker emerging?biotech spending were flagged as ongoing risks to near?term growth. Read More.
• Negative Sentiment: Market reaction: shares fell sharply on the mixed print and below?estimate top line, trading well above average volume — indicating investor concern about near?term revenue outlook. Read More.

Hedge Funds Weigh In On Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its position in Bio-Techne by 12.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock valued at $62,379,000 after acquiring an additional 113,634 shares in the last quarter. Woodline Partners LP lifted its position in Bio-Techne by 40.0% in the 1st quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock valued at $783,000 after acquiring an additional 3,814 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Bio-Techne by 506.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 562 shares in the last quarter. First Trust Advisors LP lifted its position in Bio-Techne by 1,085.7% in the 2nd quarter. First Trust Advisors LP now owns 105,418 shares of the biotechnology company’s stock valued at $5,424,000 after acquiring an additional 96,527 shares in the last quarter. Finally, Natixis lifted its position in Bio-Techne by 82.6% in the 2nd quarter. Natixis now owns 24,991 shares of the biotechnology company’s stock valued at $1,286,000 after acquiring an additional 11,306 shares in the last quarter. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.